Premium
Use of whole blood platelet lumi‐aggregometry to optimize anti‐platelet therapy in patients with chronic myeloproliferative disorders
Author(s) -
Manoharan A.,
Gemmell R.,
Hartwell T.
Publication year - 2006
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20698
Subject(s) - aspirin , medicine , clopidogrel , platelet , pharmacology , whole blood , gastroenterology
Abstract Twenty‐seven patients with chronic myeloproliferative disorders and in vitro evidence of platelet hyperactivity on whole blood platelet lumi‐aggregometry were commenced on anti‐platelet therapy comprising aspirin, clopidogrel, and/or odorless garlic and the studies were repeated to assess the efficacy of the therapeutic agent(s). Only 8 patients showed clear evidence of anti‐platelet effect while receiving the standard low‐dose (100 mg/day) aspirin therapy. Thirteen patients required a higher dosage of aspirin and/or an additional anti‐platelet agent to achieve therapeutic adequacy. Lumi‐aggregometry also proved useful to optimize therapy in the 6 patients who received clopidogrel or odorless garlic because of aspirin intolerance. Am. J. Hematol., 2006. © 2006 Wiley‐Liss, Inc.